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doi:10.1016/j.kjms.2011.11.007Abstract Nonepithelial ovarian cancer (NEOC) is a rare cancer that is often misdiagnosed as
other malignant tumors. Research on this cancer using fresh tissues is nearly impossible
because of its limited number of samples within a limited time provided. The study is to iden-
tify potential genes and their molecular pathways related to NEOC using formalin-fixed
paraffin embedded samples. Total RNA was extracted from eight archived NEOCs and seven
normal ovaries. The RNA samples with RNA integrity number >2.0, purity >1.7 and cycle count
value <28 cycles were hybridized to the Illumina Whole-Genome DASL assay (cDNA-mediated
annealing, selection, extension, and ligation). We analyzed the results using the GeneSpring
GX11.0 and FlexArray software to determine the differentially expressed genes. Microarray
results were validated using an immunohistochemistry method. Statistical analysis identified
804 differentially expressed genes with 443 and 361 genes as overexpressed and underex-
pressed in cancer, respectively. Consistent findings were documented for the overexpression
of eukaryotic translation elongation factor 1 alpha 1, E2F transcription factor 2, and fibroblast
growth factor receptor 3, except for the down-regulated gene, early growth response 1
(EGR1). The immunopositivity staining for EGR1 was found in the majority of cancer tissues.t of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz,
.uk (N.M. Mokhtar).
vier Taiwan LLC. All rights reserved.
244 K. Vui-Kee et al.This finding suggested that the mRNA level of a transcript did not always match with the
protein expression in tissues. The current gene profile can be the platform for further explo-
ration of the molecular mechanism of NEOC.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Ovarian cancer is among the most common gynecologic
cancer and it is also a leading cause of death in gynecologic
malignancies. In Malaysia, ovarian cancer accounts as the
most common cancer in women after the breast, cervix
uteri and colon. Around 1627 women in Malaysia were
diagnosed with ovarian cancer between years 2003e2005
alone. Ovarian cancer is often referred as the ‘silent killer’
due to the absence of specific symptoms and lack of
effective screening program.
Ovarian cancer is grouped into two types based on the
origin of the cells, which either arises from the surface of
epithelium or other cells of the ovary. The nonepithelial
ovarian cancer (NEOC) is the less common subtype, which
only represents about 10e15% of overall ovarian cancers
[1]. NEOC has better prognosis than the epithelial ovarian
tumor, but the recurrence rate is high which leads to the
high mortality [2].
The etiology and molecular changes of NEOC are still
poorly understood. NEOC occurs in all ages including
children, young women, and postmenopausal women;
therefore, it is imperative that these tumors are managed
with accurate diagnosis, staging, and treatment. The tumor
markers that are widely used to diagnose NEOC are CA-125,
alpha-fetoprotein, beta human chorionic gonadotropin,
inhibin, and estradiol [3e5]. However, the existing tumor
markers are not specific and sensitive enough for the
diagnosis of NEOC.
Therefore, there is a need to improve our understanding
on the molecular biology of NEOC. The common goal of this
study was to identify the potentially commonly expressed
genes that have roles in the biology of NEOC. In this report,
we used an oligonucleotide microarray to identify and
compare differential gene expression patterns in formalin
fixed paraffin embedded (FFPE) NEOC with normal ovaries
sampled from a tertiary hospital in Malaysia.
Methods
Clinical samples
This study was conducted following institutional ethical
clearance (Ref. UKM 1.5.3.5/244/SPP3). The sample size
was computed using the online calculator provided by the
University of Texas M. D. Anderson Cancer Center, Houston,
Texas, USA. The sample consists of eight NEOC and seven
normal ovaries. The archived NEOC specimens were
acquired from patients that underwent total abdominal
hysterectomy-bilateral salpingo-oophorectomy (TAHBSO)
for NEOC at the Universiti Kebangsaan Malaysia Medical
Centre, Cheras, Kuala Lumpur between the years 2002 and
2008 and patients had a mean age of 35.1  16.1 years.NEOC specimens it has been classified into five different
subtypes. Out of eight NEOC specimens, three are granulosa
cell tumors, two are mixed germ cell tumors, one is the yolk
sac tumor, one is the immature teratoma, and one is the
malignant mature teratoma. The normal ovarian tissues
were obtained from uterine fibroid patients who underwent
the TAHBSO with a mean age of 48.9  3.0 years.
RNA isolation and quality control of RNA
RNA was extracted from a pool of four to fie FFPE sections
with 5-mm thickness using the High Pure RNA Paraffin Kit
(Roche Diagnostics GmbH, Mannheim, Germany). RNA
purities were measured using NanoDrop-1000 Spectropho-
tometer (NanoDrop Technologies Inc, Wilmington, DE,
USA). RNA integrity number was evaluated using the 2100
Bioanalyzer (Agilent Technologies, Waldbronn, Germany)
with the RNA 6000 Nano kit following the manufacturer’s
protocols. A prequalification step was performed using
quantitative polymerase chain reaction using primers
product of RPL13a (accession number NM_012423.2) on
Rotor Gene (Corbett Life Science) with SensiMix One-Step
Kit (Quantace Ltd, London, United Kingdom).
Microarray assay
The WG-DASL (cDNA-mediated Annealing, Selection,
Extension, and Ligation) assay (Illumina, San Diego, CA,
USA), which quantifies 24,526 transcripts, was performed
following the manufacturer’s protocol. This assay improves
the capacity of the target set and retains the ability to
profile partially degraded RNA samples [6,7].
Statistical analysis
Microarray data analysis was performed using GeneSpring
GX11.0.2 (Agilent Technologies, Santa Clara CA, USA) and
FlexArray version 1.4.1 (Genome Quebec Innovation Centre,
Montre´al, Canada). Differential genes were identified using
the unpaired t test, at p < 0.005 and two-fold changes. The
gene set enrichment analysis (GSEA), gene ontology, and
Pathway Studio were used to understand the descriptions of
each gene product.
Validation of gene expression differences
Due to the low RNA yield from the FFPE tissues, the
immunohistochemistry (IHC) method was used as a valida-
tion tool. IHC is a practical and robust method for extending
gene expression data to common pathologic specimens
with the advantage of being applicable to FFPE tissues.
Antibodies that were used in the IHC included anti-
eukaryotic translation elongation factor 1 alpha 2 [EEF1A2
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scription factor 2 [E2F2 (Bioworld Technology, Minneapolis,
USA)], anti-fibroblast growth factor receptor 3 [FGFR3
(Abcam, Massachusetts, USA)] and anti-early growth
response 1 [EGR1 (Abcam, Massachusetts, USA)]. Antigen
was retrieved prior to staining. Endogenous peroxidaseFigure 1. Microarray data analysis in 16 nonepithelial ovarian can
analysis clustered gene expression profiling of nonepithelial ovaria
clustered together and separated from the tumor group. The blue
indicates the normal ovaries; (B) Venn diagram showing 804 signific
and FlexArray data analysis; (C) hierarchical clustering of 23 ov
expression for each gene. Samples were clustered based on 804 sign
versus normal ovaries of at least two-fold (p < 0.005). The color o
indicates genes were up-regulated above the median; green, down
The columns represent individual tissue samples; the rows represeactivity was blocked using 3% H2O2 followed by primary
antibody incubation for 30 minutes. The bound antibody
was detected using the REAL Envision Detection System
(Dako, Glostrup, Denmark) for a 30-minute incubation
period. Color was developed with 3,30 Diaminobenzidine
(DAB) for 10 minutes and counterstained with hematoxylin.cer and seven normal ovaries samples. (A) Principal component
n cancer and normal ovaries. All seven normal samples were
circle indicates the nonepithelial ovarian cancer and red circle
ant differentially expressed genes detected in both GeneSpring
aries samples graphically displays the intensity of the gene
ificant differentially expressed in nonepithelial ovarian cancers
f each square box represents the ratio of gene expression. Red
-regulated; and black, equal to the median expression signal.
nt individual genes.
Table 1 Gene set enrichments analysis with q < 0.4 using the GeneSpring GX 11.0.2 software.














0.24 0.6430 GREM1 26585 Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis), (GREM1) þ4.79 1.60E-05
NNMT 4837 Nicotinamide N-methyltransferase (NNMT) þ3.04 4.80E-04
SCN3A 6328 Sodium channel, voltage-gated, type III, alpha subunit (SCN3A), transcript
variant 1
þ3.58 4.97E-05
SPANXB1 728695 SPANX family, member B1 (SPANXB1) þ3.84 4.44E-04
BIOCARTA_G2_PATHWAY 0.28 0.5555 CCNB1 891 Cyclin B1 (CCNB1) þ9.07 1.67E-09
CDC25C 995 Cell division cycle 25 homolog C (S pombe), (CDC25C), transcript variant 2 þ10.92 4.26E-06





0.32 0.4678 CDC45L 8318 CDC45 cell division cycle 45-like (S cerevisiae), (CDC45L) þ3.85 4.02E-04
FANCD2 2177 Fanconi anemia, complementation group D2 (FANCD2), transcript variant 1 þ7.97 3.76E-06
PTTG1 9232 Pituitary tumor-transforming 1 (PTTG1) þ10.72 2.47E-06
PTTG2 10744 Pituitary tumor-transforming 2 (PTTG2) þ3.17 3.73E-05
RAD51 5888 RAD51 homolog (RecA homolog, E coli) (S. cerevisiae), transcript variant 2 þ3.39 7.55E-05
NADERI_BREAST_CANCER_
PROGNOSIS_DN
0.35 0.6113 C1S 716 Complement component 1, s subcomponent (C1S), transcript variant 1 15.79 2.19E-10
DCN 1634 Decorin (DCN), transcript variant A1 8.45 1.86E-04
SMOC2 64094 SPARC related modular calcium binding 2 (SMOC2) 3.10 1.03E-04
BIOCARTA_TEL_PATHWAY 0.32 0.6338 EGFR 1956 Epidermal growth factor receptor [erythroblastic leukemia viral
(v-erb-b) oncogene homolog, avian (EGFR)], transcript variant 1
10.83 1.80E-06
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Gene expression patterns in NEOC
The expression patterns of NEOC were analyzed based on
seven normal and duplication of eight tumor ovaries. The
principal component analysis as a quality control on arrays
samples distinctly separated the two different groups of
samples (Fig. 1A). The unpaired t test with a cutoff ratio of
at least two-fold and p < 0.005 in NEOC samples was
compared with normal ovaries (Fig. 1B). Out of these 804
genes, 443 genes were up-regulated and 361 genes were
down-regulated. The hierarchical clustering was performed
on significant genes to arrange genes and samples in groups
based on the similarity of the gene expression (Fig. 1C).
From the significant genes, positive regulation of tran-
scription from RNA polymerase II promoter was among the
significant gene set involved in biologic process. Fourteen
genes were found, including ABLIM1, CREBBP, EGR1, GRIN1,
JUN, NFAT5, NODAL, NR4A1, NR4A3, NR5A1, PBX1, SOX15,
ST5, and THRA. EGR1 was detected among the top 10 down-
regulated genes, and it was chosen for validation assay.
GSEA is a computational method that helps to connect
the gene expression profile with their biologic categories
[8]. The GSEA with q < 0.4 showed five significant gene
sets with 16 genes were overlapped with the list of 804Figure 2. Immunohistochemistry of three differentially gene pr
Negative immunostaining of EEF1A2, E2F2, and FGFR3 on a normal
cytoplasmic staining in granulosa cell tumors and mixed germ cell
E2F2 shows cytoplasmic positivity and a few positive nuclei in both
predominantly in the membrane protein and stromal signals. Ori
EEF1A2 Z eukaryotic translation elongation factor 1 alpha 2; FBFR
ovarian cancer.significant genes [p < 0.005 (Table 1)]. The MAHADEVA-
N_IMATINIB_RESISTANCE_UP was the most enriched gene
set, including GREM1, NNMT, SCN3A, and SPANXB.
The Pathway Studio analysis showed direct interaction
of significant genes involved in cancers and ovarian cancer.
The E2F2 and EGR1 were found to be associated with the
MDM2 gene in BIOCARTA_G2_PATHWAY. The EEF1A2, E2F2,
and EGR1 showed to have direct interaction with ovarian
cancer, while FGFR3 has a direct interaction with other
cancers. We chose EGR1, E2F2, EEF1A2, and FGFR3 for
further validation assay.
IHC
The results for IHC were based on 16 normal and 16 NEOC
specimens. Positive immunostaining was detected in NEOC
samples for EEF1A2, E2F2, and FGFR3 (Fig. 2). EEF1A2
immunostaining was parallel with mRNA expression in the
microarray data. High expression of EEF1A2 protein was
detected in the cytoplasm of granulosa cell tumors and
mixed germ cell tumors of dysgerminoma tissues (Fig. 2B
and C). Immunostaining for E2F2 in NEOC was also consis-
tent with microarray data, showing a moderate to strong
cytoplasmic and focally nuclear staining (Fig. 2E, F). The
high FGFR3 mRNA expression in NEOC was consistently
reflected in the moderate to strong staining ofoducts in nonepithelial ovarian tissue samples. (A, D, and G)
ovary; (B and C) positive immunostaining of EEF1A2 with strong
tumors of dysgerminoma tissues; (E and F) immunostaining for
NEOC subtypes; (H and I) positive immunostaining for FGFR3 is
ginal magnification 400. E2F2 Z E2F transcription factor 2;
3 Z fibroblast growth factor receptor 3; NEOC Z nonepithelial
Table 2 Summary of IHC results.
EEF1A2 E2F2 FGFR3 EGR1
NEOC subtype
Granulosa cell tumor 6/6 6/6 6/6 4/6
Juvenile granulosa
cell tumor
1/1 1/1 1/1 1/1
Mixed germ cell tumor 2/2 2/2 2/2 2/2
Yolk sac tumor 2/2 2/2 2/2 2/2
Immature teratoma 1/1 1/1 1/1 1/1
Malignant mature teratoma 1/1 1/1 1/1 0/1
Dysgerminoma 2/2 2/2 2/2 2/2









E2F2 Z E2F transcription factor 2; EEF1A2 Z eukaryotic
translation elongation factor 1 alpha 2; EGR1 Z early growth
response 1; FBFR3 Z fibroblast growth factor receptor 3;
IHC Z immunohistochemistry; NEOC Z nonepithelial ovarian
cancer.
248 K. Vui-Kee et al.predominantly membranous and some of the cytoplasm
(Fig. 2H and I). The validation experiment for EGR1 showed
an opposite result. Our microarray data showed down-
regulation of EGR1 in NEOC, but the IHC result exhibited
strong expression in all normal ovaries (Fig. 3A and B) as
well as in 13 of the 16 NEOC samples (Fig. 3C). Only three of
the 16 NEOC samples gave negative expression of EGR1
(Fig. 3D). The summary of IHC results on NEOC subtypes
shown in Table 2. The validation data were shown in
Table 3.
Discussion
Several published studies have reported the use of micro-
array analysis in gene expression on ovarian neoplasm but
those are limited to the epithelial ovarian cancer subtypes
[9e11]. In the current study, we focused on analyzing the
gene expression of NEOC. The availability of kits to extract
RNA from the archived tissues for genome wide expression
analysis has provided a great opportunity to characterize
the molecular profiles of this tumor despite its rarity and
limited availability of fresh tissues.
To assess the differential gene expression in NEOC, we
have performed a microarray study using WG-DASL assay.
The NEOC is a heterogenous group of malignancies at
both the histologic and genetic levels. These are all
uncommon cancers. They are rare, and the literature is
sparse with regard to the diagnosis and prognosis of thisFigure 3. Immunohistochemistry of EGR1 for the validation of
nucleus and cytoplasmic in all the normal ovaries; (C) positive immu
(D) negative immunostaining of EGR1 in the minority of NEOC sampl
1; NEOC Z nonepithelial ovarian cancer.cancer. The molecular pathways involved in the patho-
genesis of NEOC are still largely unknown. A profile of the
common significant genes from different NEOC subtypes has
been identified. There were 804 genes differentially
expressed with at least two-fold change (p < 0.005). GSEA
showed the connection between the significant genes thatmicroarray data. (A, B) Positive immunostaining of EGR1 with
nostaining of EGR1 is seen in the majority of the NEOC samples;
es. Original magnification 400. EGR1Z early growth response
Table 3 Expression of genes and protein in NEOC by microarray and immunohistochemistry analysis.
Gene/protein Microarray data Protein expression positive/
NEOC specimensa by IHC
Staining pattern
EEF1A2 Up-regulated 41.14-fold 16/16 Cytoplasmic
E2F2 Up-regulated 34.53-fold 16/16 Cytoplasmic and nuclei
FGFR3 Up-regulated 20.93-fold 16/16 Cell membrane
EGR1 Down-regulated 29.81-fold 13/16 Cytoplasmic and nuclei
This table shows the expression level of four significant genes in NEOC compared with normal ovaries.
IHC Z immunohistochemistry; NEOC Z nonepithelial ovarian cancer.
a NEOC specimens (nZ 16) with confirmed diagnosis of NEOC. Cases with at least minimal focal staining were defined to be positive.
Expression in nonepithelial ovarian cancer 249share the common biologic functions. Among the significant
pathways involved was the BIOCARTA_G2_PATHWAY, and
MDM2 was identified as one of the significant genes. This
pathway involved in the cell cycle phases, where there is
a period of rapid cell growth and synthesis of protein for
mitosis [12]. The increased level of MDM2 could be a result
of various mechanisms, including enhanced translation and
the inactivation of apoptotic and cell cycle arrest function
of the p53 tumor suppressor gene [12,13]. MDM2 has an
ability to inhibit the activity of the p53 and commonly
occurs in the genesis of many tumors.
EEF1A2 was found to be highly expressed in NEOC
compared to normal ovaries. This gene normally has high
expression in muscles, neurons, and the heart [14]. A
previous study reported that EEF1A2 was identified as an
important player in the progression of tumors including that
of the breast, lung, and ovary [15]. The high expression of
EEF1A2 has implied that this gene possibly acts as an
oncogene, activates tumorigenesis, and regulates apoptosis
[16]. The high expression of EEF1A2 was supported by
previous studies in breast cancer [17], epithelial ovarian
cancer [15,18], and the hepatocellular carcinoma cell line,
JHH6 [19].
Several others cancer genes were also overexpressed in
NEOC, notably E2F2. Our findings are in agreement with
previous studies in ovarian cancer and ovarian cell lines
[20e22]. E2F2 was consistently overexpressed in NEOC.
E2F2, which belongs to the E2F family, plays an important
role in controlling cell cycle and acts as a tumor suppressor
protein [23,24]. The abnormal activity of E2F transcription
factor is the key event in development of most human
cancers and may alter the p16-cyclin D-Rb pathway [21,23].
Previous studies have revealed that the overexpression of
E2F2 may cause an excess of proliferation-promoting
stimuli to the cancer cells [20]. The up-regulation of E2F2
in ovarian cancer cell lines may contribute to the uncon-
trolled proliferation and may also be associated with the
highly malignant and fast growing tumors. Positive staining
of E2F2 has suggested the high possibility of this gene acting
as an oncogene in NEOC.
FGFR3 belongs to the fibroblast growth factor family,
which is involved in various biologic processes, including
cell growth, motility, differentiation, and angiogenesis
[25]. Recent reports showed that deregulation of FGFR3
might affect cell growth and proliferation [25]. The high
expression of FGFR3 as identified by our microarray as well
as the IHC is consistent with findings in other cancers such
as prostate carcinoma, cervical cancer, and myeloma [26].EGR1 is a transcription factor involved in various biologic
functions such as regulation of proliferation, growth,
apoptosis and angiogenesis [27]. It was reported to be
associated with cancer progression. In our study, we did not
observe a consistent result between the microarray and
IHC. The EGR1 showed positive immunostaining in NEOC
despite showing low expression in the microarray data. The
positive finding from IHC is consistent with the previous
studies on high expression of EGR1 in prostate cancer [28].
The inconsistency of this result might also be explained by
the low correlation between mRNA expression of this gene
and its protein expression [29]. This could be due to bio-
logic factors such as the complexity of the mechanisms
involved between transcription and translation.
In conclusion, the present study successfully examined
the gene expression profile of NEOC from a highly degraded
FFPE samples using the oligonucleotide microarray assay. A
set of significant genes was found to be differentially
expressed in NEOC. This is the first local data that will be an
informative platform for the future studies on the NEOC.
Multiple NEOC subtypes did not make the data homoge-
nous. Therefore, further studies using larger number of
samples for each NEOC subtypes may be necessary to
address the roles of cancer related genes and their biologic
functions involved in NEOC.Acknowledgment
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